Kim Callender, NP, FNP-BC
Lead Clinical Reviewer
Kim Callender, FNP-BC is a board-certified family nurse practitioner and the lead clinical reviewer for GLP-1 Price Index. She reviews patient-journey, clinical-workflow and care-model content: intake quality, prescriber review processes, follow-up access, refill workflows and support escalation. Her NPI record (1144661760) is listed in the CMS NPPES registry.
Credentials & verification
- Role
- Lead Clinical Reviewer
- NPI
- 1144661760 — verified in the CMS National Plan & Provider Enumeration System registry
- Review scope
- Clinical workflow and patient-care review: provider reviews, care-model comparisons, support testing.
- Verification
- NPI record checked against the CMS NPPES registry.
Conflict disclosure
Kim Callender, NP, FNP-BC is not compensated based on any reviewed provider's sales. Where a page involves NexLife, our ownership relationship is disclosed on that page, and the NexLife score is signed off by an unaffiliated reviewer. See our conflicts-of-interest policy.
Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.
Role and scope
Kim Callender, NP, FNP-BC — Lead Clinical Reviewer. NPI 1144661760, verified against the CMS National Plan and Provider Enumeration System.
Kim Callender writes and reviews clinical content: mechanism of action, dosing and titration, side effects, contraindications, drug interactions and monitoring. She reviews every page that describes what a medication does to the body.
What we publish, and what we deliberately do not
This profile contains only information that has been confirmed to us. We publish the name, the credential, the editorial role, the scope of review, and — where it exists — an NPI that we have checked against the CMS registry.
We do not publish specialty, board certification, state licence, hospital affiliation, university affiliation, awards, professional memberships, or biography unless each has been separately verified. Padding a reviewer profile with unverified professional detail is one of the commonest ways a health site manufactures authority, and we would rather this page look thin than look impressive on facts we cannot stand behind.
Conflict disclosure
Relationships the publisher has confirmed to date are named on the ownership disclosure. Where a provider is not named there, that is because the publisher has not confirmed a relationship — it is not a statement that we have verified its absence. We would rather show you that gap than imply an independence we have not checked.
Compensation does not increase the price you pay, and does not permit any provider to purchase a verification status, alter a documented fact, remove a material limitation, change a ranking, or bypass our published editorial and medical-review standards.
No reviewer on this site is compensated based on any provider’s sales, and no employee, executive or medical director of any reviewed provider writes, reviews, scores or approves that provider’s page. NexLife’s medical director, Dr. Adam Kennah, has no role in our editorial process. We name him on the NexLife review because he is a fact about NexLife — not because he has anything to do with our independence.
The numbers behind this page
What we do not claim in this page
Every price quoted in this page comes from the programme's own pricing page and carries the date it was captured.
We do not claim these prices will hold. Compounded pricing moves within weeks, and a figure without a capture date is not a fact. We do not claim a compounded preparation is equivalent to an approved product: it is not FDA-approved, is not therapeutically equivalent to any brand-name product, and FDA does not review it for safety, effectiveness or manufacturing quality before marketing.
And we do not claim to be a clinical resource. Which molecule suits you, at what dose, and whether treatment is appropriate at all are questions for a prescribing clinician who has your history. This is price research, and it is only useful once those questions are settled.
Reading the price against the market
What the plan term is worth
The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
What the plan term is worth
The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
Questions this page answers
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.
Where do these prices come from?
Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.
What is the cheapest verified GLP-1 programme?
NexLife at $119 a month for semaglutide and $139 for tirzepatide on its 12-month plan, both at standard therapeutic dosing and first-party verified September 4, 2026. Month-to-month, NexLife is $139 and $169; Oak Longevity ($133, flat, no membership) is the next-cheapest semaglutide programme.